Linked Life Data

16608976

Source:http://linkedlifedata.com/resource/pubmed/id/16608976

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-4-12
pubmed:abstractText
Patients with resectable stage IIIA-N2 non-small cell lung cancer should receive induction chemotherapy before surgery. The aim is to early control systemic disease, eventually cure the mediastinal tumor spread and improve patients' survival. A recent metanalysis of randomized trials with second-generation platinum-based combinations has reinforced the evidence concerning the benefit of induction chemotherapy followed by surgery versus surgery alone in resectable disease. Moreover a large number of phase II trials have explored the activity and feasibility of platinum-based combinations with third-generation drugs in the same setting. Still opened questions to address with current clinical research are the eventual role of radiotherapy as induction treatment, the impact of definite chemoradiation versus induction treatment followed by surgical resection on local control and survival and finally the non-easy choice between neo-adjuvant and adjuvant chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
17 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
ii28-31
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Locally advanced non-small cell lung cancer: role of induction chemotherapy in resectable N2 disease.
pubmed:affiliation
5th Pneumo-Oncology Unit, Department of Lung Diseases, San Camillo-Forlanini Hospitals, Rome, Italy.
pubmed:publicationType
Journal Article, Review